Company Profile

O2 RegenTech LLC
Profile last edited on: 7/3/19      CAGE: 75YG0      UEI: Y27TXM697LZ6

Business Identifier: Cost-effective, easy-to-use chronic wound care
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

411 Wolf Ledges Parkway Suite 100
Akron, OH 44311
   (267) 231-8908
Location: Single
Congr. District: 11
County: Summit

Public Profile

O2 RegenTech, a medical device startup out of the University of Akron, is working on development of OXAID, a dressing for the treatment of chronic wounds with particular focus on would care. Initially targeted to those suffering from diabetic foot ulcers, 02 RegenTech's product differs from current hydrogel wound dressings in that its patent-pending technology combines moisture, oxygen and antimicrobial properties more effectively to heal wounds. This technique, it is suggested, is more cost-effective and could allows for faster recovery than traditional chronic wound dressings. The three most important factors in wound healing are oxygen, moisture, and protection from bacteria to prevent infections. Currently, it is suggested, no wound treatments are available that offer all three components at once, requiring patients to use a combination of different bandages, dressings, ointments, and other treatments. O2 RegenTech's objective is to make wound care simpler with its proprietary product, OXAID™, a treatment that provides all three important components to promote wound healing in one easy-to-use dressing

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 1 NSF $225,000
Project Title: Tunable Oxygenating Biopolymer Hydrogel Dressings for Chronic Wound Care
2016 1 NIH $224,977
Project Title: Oxaid: Oxygenating Hydrogel for Diabetic Wound Care

Key People / Management

  Andreas Inmann -- Founder, President & CEO

  Nic Leipzig